Our study provides critical pre-clinical evidence for repurposing CCK/CCKAR antagonists, many of them already developed for gastrointestinal diseases61, to treat obesity-associated asthma. This evidence concerns the gene CCK and obesity due to melanocortin 4 receptor deficiency.